Innate Pharma (IPHA) Total Debt (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Total Debt data on file, last reported at $26.3 million in Q4 2025.

• For the quarter ending Q4 2025, Total Debt fell 20.67% year-over-year to $26.3 million; the trailing twelve-month figure through Dec 2025 stood at $26.3 million (down 20.67% YoY), and the FY2025 full-year result was $26.3 million, down 20.67% from the prior year.
• Total Debt for Q4 2025 stood at $26.3 million, down from $30.6 million in the prior quarter.
• Across five years, Total Debt topped out at $50.6 million in Q4 2021 and bottomed at $19.9 million in Q2 2021.
• The 5-year median for Total Debt is $40.6 million (2023), against an average of $37.5 million.
• The widest annual swing landed in 2021, when Total Debt tumbled 99.89%; it then jumped 132.89% in 2022.
• A 5-year view of Total Debt shows it stood at $50.6 million in 2021, then declined by 14.85% to $43.1 million in 2022, then retreated by 0.43% to $42.9 million in 2023, then retreated by 22.84% to $33.1 million in 2024, then retreated by 20.67% to $26.3 million in 2025.
• The last three Total Debt figures came in at $26.3 million (Q4 2025), $30.6 million (Q2 2025), and $33.1 million (Q4 2024), per Business Quant data.

Peer Comparison